ArticleEClinicalMedicine2023

Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study.

Howard Sofen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.